Bioinformatics Market Will Reach $11.43bn in 2020

Monday 28 November 2016, Amsterdam

A new report, now available on ASDReports, forecasts the overall world bioinformatics market will achieve revenue of $11.43 billion in 2020. Revenues will more than triple overall from 2015 to 2026 as bioinformatic technologies become increasingly adopted in drug discovery and other applications. Multilevel predictions for those technologies appear in Bioinformatics Market Analysis, Developments and Forecasts 2016-2026: Revenue Predictions for Genomics, Metabolomics, Proteomics, Transcriptomics, Chemoinformatics and Drug Discovery Applications; Sales Breakdowns for the US, EU, Japan, China and India; and Discussion of Personalised Medicine, Pharmacogenomics, Next-Generation Sequencing, Diagnostic Biomarkers and Big Data.

That investigation analyses developments and sales opportunities shaping bioinformatics. The work shows revenue forecasting and qualitative analyses. It also examines activities of leading companies. Its purpose is to help organisations explore commercial potentials of industries and markets in healthcare and other fields.

Bioinformatic analysis involves the use of software to find new drug treatments and analyse the vast amounts of biological data that have been generated in recent years, especially with the use of NGS (next-generation sequencing). NGS costs have become greatly reduced, which will encourage companies to invest in it and use bioinformatics to interpret the resulting information into practical clinical applications.

This study predicts expansion in the bioinformatics market will continue until 2026, especially in the genomics sector, which will remain dominant. The chemo informatics and drug discovery sector will have the highest revenue growth rate during this period, as the use of bioinformatics in personalised medicine increases. In 2015, the genomics submarket formed the most lucrative part of that industry, accounting for 48.6% of the overall world market. As the bioinformatics market grows, this segment will continue to dominate.

The report’s author said:

 “The bioinformatics market has strong potential, with many innovative software platforms that can offer analysis of not only genomic data but proteomic, transcriptomic and chemoinformatic data. With so many sources of data, a company that can offer integrated analysis and interpretation will have a competitive edge. Researchers will also be looking to bioinformatics companies to provide security and flexibility such as cloud-based bioinformatics to facilitate collaborations and enable data access from anywhere. An important restraint on growth of the market will be a shortage of trained expertise; over our forecast period the success of the market will depend on remedying this deficit. The bioinformatics market will continue to expand, bolstered by governmental investment and lower costs of sequencing, as the trend towards personalised medicine ensures that demand stays strong.”